Modulation of dendritic cell function by PGE2 and DHA: A framework for understanding the role of dendritic cells in neuroinflammation

Clinical Lipidology

Volumn 6, Issue 3, 2011, Pages 277-291

  Ganea, Doina ^a   Kocieda, Virginia ^a   Kong, Weimin ^a   Yen, Jui Hung ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dendritic cells; docosahexaenoic acid; lipid mediators; neuroinflammation; PGE2; T cell differentiation

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID DERIVATIVE; BEHENIC ACID; CD4 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPENTENONE DERIVATIVE; CYTOKINE; DOCOSAHEXAENOIC ACID; FATTY ACID DERIVATIVE; FENRETINIDE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; MARESIN; NEUROPROSTANE; NEUROPROTECTIN D1; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PROSTAGLANDIN E2; RESOLVIN D1; RESOLVIN E1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE PRODUCTION; DEMENTIA; DENDRITIC CELL; DIET SUPPLEMENTATION; EFFECTOR CELL; ENCEPHALITIS; HUMAN; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SENILE PLAQUE; SPINAL CORD INJURY; T LYMPHOCYTE ACTIVATION;

EID: 79959393876     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.12     Document Type: Review

References (118)

1. Wee Yong V: Inflammation in neurological disorders: a help or a hindrance? Neuroscientist 16(4), 408-420 (2010).
2. Bannenberg G, Serhan CN: Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim. Biophys. Acta 1801(12), 1260-1273 (2010).
3. Narumiya S: Prostanoids and inflammation: a new concept arising from receptor knockout mice. J. Mol. Med. 87(10), 1015-1022 (2009).
4. Rinaldo-Matthis A, Haeggstrom JZ: Structures and mechanisms of enzymes in the leukotriene cascade. Biochimie 92(6), 676-681 (2010).
5. Ryan A, Godson C: Lipoxins: regulators of resolution. Curr. Opin. Pharmacol. 10(2), 166-172 (2010).
6. Comabella M, Montalban X, Munz C, Lunemann JD: Targeting dendritic cells to treat multiple sclerosis. Nat. Rev. Neurol. 6(9), 499-507 (2010).
7. Felger JC, Abe T, Kaunzner UW et al.: Brain dendritic cells in ischemic stroke: time course, activation state, and origin. Brain Behav. Immun. 24(5), 724-737 (2010)
8. Gelderblom M, Leypoldt F, Steinbach K et al.: Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 40(5), 1849-1857 (2009).
9. Israelsson C, Bengtsson H, Lobell A et al.: Appearance of Cxcl10-expressing cell clusters is common for traumatic brain injury and neurodegenerative disorders. Eur. J. Neurosci. 31(5), 852-863 (2010).
10. Zozulya AL, Clarkson BD, Ortler S, Fabry Z, Wiendl H: The role of dendritic cells in CNS autoimmunity. J. Mol. Med. 88(6), 535-544 (2010).
11. Manz MG, Traver D, Akashi K et al.: Dendritic cell development from common myeloid progenitors. Ann. NY Acad. Sci. 938, 167-173; discussion 73-74 (2001).
12. Liu K, Nussenzweig MC: Development and homeostasis of dendritic cells. Eur. J. Immunol. 40(8), 2099-2102 (2010).
13. Liu K, Nussenzweig MC: Origin and development of dendritic cells. Immunol. Rev. 234(1), 45-54 (2010).
14. Naik SH, Metcalf D, van Nieuwenhuijze A et al.: Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat. Immunol. 7(6), 663-671 (2006). (Pubitemid 43797348)
15. Varol C, Vallon-Eberhard A, Elinav E et al.: Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity 31(3), 502-512 (2009).
16. Hart DN, Fabre JW: Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J. Exp. Med. 154(2), 347-361 (1981). (Pubitemid 11044167)
17. Matyszak MK, Perry VH: The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience 74(2), 599-608 (1996) (Pubitemid 26274227)
18. McMenamin PG: Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J. Comp. Neurol. 405(4), 553-562 (1999). (Pubitemid 29124070)
19. Serot JM, Bene MC, Foliguet B, Faure GC: Monocyte-derived IL-10-secreting dendritic cells in choroid plexus epithelium. J. Neuroimmunol. 105(2), 115-119 (2000). (Pubitemid 30160747)
20. Bulloch K, Miller MM, Gal-Toth J et al.: CD11c/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain. J. Comp. Neurol. 508(5), 687-710 (2008) (Pubitemid 351693557)
21. Hanly A, Petito CK: HLA-DR-positive dendritic cells of the normal human choroid plexus: a potential reservoir of HIV in the central nervous system. Hum. Pathol. 29(1), 88-93 (1998). (Pubitemid 28049551)
22. Pashenkov M, Huang YM, Kostulas V, Haglund M, Soderstrom M, Link H: Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain 124(Pt 3), 480-492 (2001). (Pubitemid 32221315)
23. Fischer HG, Reichmann G: Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J. Immunol. 166, 4, 2717-2726 (2001). (Pubitemid 32173513)
24. Santambrogio L, Belyanskaya SL, Fischer FR et al.: Developmental plasticity of CNS microglia. Proc. Natl Acad. Sci. USA 98(11), 6295-6300 (2001). (Pubitemid 32488233)
25. Mikami Y, Okano H, Sakaguchi M et al.: Implantation of dendritic cells in injured adult spinal cord results in activation of endogenous neural stem/progenitor cells leading to de novo neurogenesis and functional recovery. J. Neurosci. Res. 76(4), 453-465 (2004). (Pubitemid 38580461)
26. McMahon EJ, Bailey SL, Miller SD: CNS dendritic cells: critical participants in CNS inflammation? Neurochem. Int. 49(2), 195-203 (2006). (Pubitemid 43867078)
27. Reichmann G, Schroeter M, Jander S, Fischer HG: Dendritic cells and dendritic-like microglia in focal cortical ischemia of the mouse brain. J. Neuroimmunol. 129(1-2), 125-132 (2002). (Pubitemid 34874917)
28. Kostulas N, Li HL, Xiao BG, Huang YM, Kostulas V, Link H: Dendritic cells are present in ischemic brain after permanent middle cerebral artery occlusion in the rat. Stroke 33(4), 1129-1134 (2002). (Pubitemid 34293602)
29. Newman TA, Galea I, van Rooijen N, Perry VH: Blood-derived dendritic cells in an acute brain injury. J. Neuroimmunol. 166(1-2), 167-172 (2005). (Pubitemid 41074666)
30. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH: T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162(1), 1-11 (2010).
31. Serafini B, Columba-Cabezas S, Di Rosa F, Aloisi F: Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am. J. Pathol. 157(6), 1991-2002 (2000).
32. Suter T, Malipiero U, Otten L et al.: Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. Eur. J. Immunol. 30(3), 794-802 (2000). (Pubitemid 30216251)
33. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD: Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11(3), 335-339 (2005) (Pubitemid 40460563)
34. Suter T, Biollaz G, Gatto D et al.: The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation. Eur. J. Immunol. 33(11), 2998-3006 (2003). (Pubitemid 37428332)
35. Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F: Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148(1-2), 11-23 (2004). (Pubitemid 38229554)
36. Greter M, Heppner FL, Lemos MP et al.: Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11(3), 328-334 (2005). (Pubitemid 40460562)
37. Kivisakk P, Mahad DJ, Callahan MK et al.: Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann. Neurol. 55(5), 627-638 (2004). (Pubitemid 38544322)
38. Plumb J, Armstrong MA, Duddy M, Mirakhur M, McQuaid S: CD83-positive dendritic cells are present in occasional perivascular cuffs in multiple sclerosis lesions. Mult. Scler. 9(2), 142-147 (2003). (Pubitemid 36426988)
39. Fabry Z, Schreiber HA, Harris MG, Sandor M: Sensing the microenvironment of the central nervous system: immune cells in the central nervous system and their pharmacological manipulation. Curr. Opin. Pharmacol. 8(4), 496-507 (2008).
40. Owens T, Bechmann I, Engelhardt B: Perivascular spaces and the two steps to neuroinflammation. J. Neuropathol. Exp. Neurol. 67(12), 1113-1121 (2008).
41. Zozulya AL, Reinke E, Baiu DC, Karman J, Sandor M, Fabry Z: Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1a chemokine and matrix metalloproteinases. J. Immunol. 178(1), 520-529 (2007). (Pubitemid 46033636)
42. Becher B, Bechmann I, Greter M: Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J. Mol. Med. 84(7), 532-543 (2006). (Pubitemid 43992845)
43. Bailey SL, Schreiner B, McMahon EJ, Miller SD: CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat. Immunol. 8(2), 172-180 (2007) (Pubitemid 46152648)
44. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM: IL-12-and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205(7), 1535-1541 (2008). (Pubitemid 351962016)
45. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM: Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 14(3), 337-342 (2008). (Pubitemid 351347910)
46. Shimonkevitz R, Colburn C, Burnham JA, Murray RS, Kotzin BL: Clonal expansions of activated g/d T cells in recent-onset multiple sclerosis. Proc. Natl Acad. Sci. USA 90(3), 923-927 (1993). (Pubitemid 23053922)
47. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH: Interleukin-1 and IL-23 induce innate IL-17 production from gd T cells, amplifying Th17 responses and autoimmunity. Immunity 31(2), 331-341 (2009)
48. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA: gd T-cell receptor repertoire in acute multiple sclerosis lesions. Proc. Natl Acad. Sci. USA 89(10), 4588-4592 (1992).
49. Petermann F, Rothhammer V, Claussen MC et al.: gd T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity 33(3), 351-363 (2010).
50. Zozulya AL, Ortler S, Lee J et al.: Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS. J. Neurosci. 29(1), 140-152 (2009).
51. Adibhatla RM, Hatcher JF: Altered lipid metabolism in brain injury and disorders. Subcell. Biochem. 49, 241-268 (2008).
52. Farooqui AA, Horrocks LA, Farooqui T: Modulation of inflammation in brain: a matter of fat. J. Neurochem. 101(3), 577-599 (2007). (Pubitemid 46633316)
53. Phillis JW, Horrocks LA, Farooqui AA: Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Rev. 52(2), 201-243 (2006). (Pubitemid 44291802)
54. Tassoni D, Kaur G, Weisinger RS, Sinclair AJ: The role of eicosanoids in the brain. Asia Pac. J. Clin. Nutr. 17(Suppl. 1), 220-228 (2008).
55. Svennerholm L: Distribution and fatty acid composition of phosphoglycerides in normal human brain. J. Lipid Res. 9(5), 570-579 (1968).
56. Gilroy DW: Eicosanoids and the endogenous control of acute inflammatory resolution. Int. J. Biochem. Cell Biol. 42(4), 524-528 (2010).
57. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN: Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278(17), 14677-14687 (2003). (Pubitemid 36799790)
58. Orr SK, Bazinet RP: The emerging role of docosahexaenoic acid in neuroinflammation. Curr. Opin. Investig. Drugs 9(7), 735-743 (2008). (Pubitemid 351950870)
59. Serhan CN, Chiang N, Van Dyke TE: Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8(5), 349-361 (2008). (Pubitemid 351595216)
60. Stables MJ, Gilroy DW: Old and new generation lipid mediators in acute inflammation and resolution. Prog. Lipid Res. 50(1), 35-51 (2010).
61. Montuschi P, Barnes P, Roberts LJ 2nd: Insights into oxidative stress: the isoprostanes. Curr. Med. Chem. 14(6), 703-717 (2007). (Pubitemid 46477722)
62. Musiek ES, Brooks JD, Joo M et al.: Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J. Biol. Chem. 283(29), 19927-19935 (2008).
63. Kang SS, McGavern DB: Inflammation on the mind: visualizing immunity in the central nervous system. Curr. Top. Microbiol. Immunol. 334, 227-263 (2009).
64. Perry VH, Nicoll JA, Holmes C: Microglia in neurodegenerative disease. Nat. Rev. Neurol. 6(4), 193-201 (2009).
65. Serhan CN: Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J. Thromb. Haemost. 7(Suppl. 1), 44-48 (2009).
66. Farooqui AA: Lipid mediators in the neural cell nucleus: their metabolism, signaling, and association with neurological disorders. Neuroscientist 15(4), 392-407 (2009).
67. Kaufmann WE, Andreasson KI, Isakson PC, Worley PF: Cyclooxygenases and the central nervous system. Prostaglandins 54(3), 601-624 (1997). (Pubitemid 27495921)
68. Kudo I, Murakami M: Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 68-69, 3-58 (2002).
69. Gilroy DW, Newson J, Sawmynaden P, Willoughby DA, Croxtall JD: A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. FASEB J. 18(3), 489-498 (2004). (Pubitemid 38326305)
70. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2(7), 612-619 (2001). (Pubitemid 32677628)
71. Andreasson K: Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat. 91(3-4), 104-112 (2010).
72. Choi SH, Aid S, Bosetti F: The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. TrendsPharmacol. Sci. 30(4), 174-181 (2009).
73. Cimino PJ, Keene CD, Breyer RM, Montine KS, Montine TJ: Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr. Med. Chem. 15(19), 1863-1869 (2008).
74. Dore S, Otsuka T, Mito T et al.: Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann. Neurol. 54(2), 155-162 (2003). (Pubitemid 36909614)
75. Iadecola C, Niwa K, Nogawa S et al.: Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl Acad. Sci. USA 98(3), 1294-1299 (2001). (Pubitemid 32121226)
76. Ahmad M, Zhang Y, Liu H, Rose ME, Graham SH: Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. Brain Res. 1279, 168-173 (2009).
77. Ikeda-Matsuo Y, Ota A, Fukada T, Uematsu S, Akira S, Sasaki Y: Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc. Natl Acad. Sci. USA 103(31), 11790-11795 (2006). (Pubitemid 44182529)
78. Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Dore S: Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res. 1066(1-2), 71-77 (2005). (Pubitemid 41790730)
79. Ahmad AS, Yun YT, Ahmad M, Maruyama T, Dore S: Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation. Neurotox. Res. 14(4), 343-351 (2008).
80. Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K: Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci. Lett. 438(2), 210-215 (2008).
81. Liu D, Wu L, Breyer R, Mattson MP, Andreasson K: Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann. Neurol. 57(5), 758-761 (2005). (Pubitemid 40628868)
82. McCullough L, Wu L, Haughey N et al.: Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 24(1), 257-268 (2004). (Pubitemid 38181690)
83. Saleem S, Kim YT, Maruyama T, Narumiya S, Dore S: Reduced acute brain injury in PGE2 EP3 receptor-deficient mice after cerebral ischemia. J. Neuroimmunol. 208(1-2), 87-93 (2009).
84. Saleem S, Ahmad AS, Maruyama T, Narumiya S, Dore S: PGF(2a) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox. Res. 15(1), 62-70 (2009).
85. Hoshino T, Namba T, Takehara M et al.: Prostaglandin E2 stimulates the production of amyloid-b peptides through internalization of the EP4 receptor. J. Biol. Chem. 284(27), 18493-18502 (2009).
86. Arvanitakis Z, Grodstein F, Bienias JL et al.: Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70(23), 2219-2225 (2008).
87. Szekely CA, Green RC, Breitner JC et al.: No advantage of Ab42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70(24), 2291-2298 (2008).
88. Sonnen JA, Larson EB, Walker RL et al.: Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 75(13), 1203-1210 (2010).
89. Thoonsen H, Richard E, Bentham P et al.: Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern? Stroke 41(11), 2690-2692 (2010).
90. Liang X, Wang Q, Shi J et al.: The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann. Neurol. 64(3), 304-314 (2008).
91. Cudkowicz ME, Shefner JM, Schoenfeld DA et al.: Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 60(1), 22-31 (2006).
92. Gagne JJ, Power MC: Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74(12), 995-1002 (2010).
93. Bettelli E, Oukka M, Kuchroo VK: T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8(4), 345-350 (2007). (Pubitemid 46745409)
94. Kebir H, Kreymborg K, Ifergan I et al.: Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13(10), 1173-1175 (2007). (Pubitemid 47530640)
95. Khayrullina T, Yen JH, Jing H, Ganea D: In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/ IL-23 balance and promotes differentiation of Th17 cells. J. Immunol. 181(1), 721-735 (2008).
96. Sheibanie AF, Khayrullina T, Safadi FF, Ganea D: Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/ interleukin-17 axis. Arthritis Rheum. 56(8), 2608-2619 (2007). (Pubitemid 47237279)
97. Sheibanie AF, Tadmori I, Jing H, Vassiliou E, Ganea D: Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J. 18(11), 1318-1320 (2004). (Pubitemid 39561589)
98. Sheibanie AF, Yen JH, Khayrullina T et al.: The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23->IL-17 axis. J. Immunol. 178(12), 8138-8147 (2007). (Pubitemid 46898086)
99. Boniface K, Bak-Jensen KS, Li Y et al.: Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 206(3), 535-548 (2009).
100. Yao C, Sakata D, Esaki Y et al.: Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 15(6), 633-640 (2009).
101. Kihara Y, Matsushita T, Kita Y et al.: Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc. Natl Acad. Sci. USA 106(51), 21807-21812 (2009).
102. Esaki Y, Li Y, Sakata D et al.: Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 107(27), 12233-12238 (2010).
103. Hamilton JA, Brunaldi K: A model for fatty acid transport into the brain. J. Mol. Neurosci. 33(1), 12-17 (2007). (Pubitemid 47574951)
104. Ouellet M, Emond V, Chen CT et al.: Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem. Int. 55(7), 476-482 (2009).
105. Green JT, Orr SK, Bazinet RP: The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids. J. Lipid Res. 49(5), 939-944 (2008).
106. Niemoller TD, Bazan NG: Docosahexaenoic acid neurolipidomics. Prostaglandins Other Lipid Mediat. 91(3-4), 85-89 (2010).
107. Groeger AL, Cipollina C, Cole MP et al.: Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat. Chem. Biol. 6(6), 433-441 (2010).
108. Hamilton JA, Brunaldi K: A model for fatty acid transport into the brain. J. Mol. Neurosci. 33(1), 12-17 (2007). (Pubitemid 47574951)
109. Ouellet M, Emond V, Chen CT et al.: Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem. Int. 55(7), 476-482 (2009).
110. Green JT, Orr SK, Bazinet RP: The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids. J. Lipid Res. 49(5), 939-944 (2008).
111. Niemoller TD, Bazan NG: Docosahexaenoic acid neurolipidomics. Prostaglandins Other Lipid Mediat. 91(3-4), 85-89 (2010).
112. Groeger AL, Cipollina C, Cole MP et al.: Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat. Chem. Biol. 6(6), 433-441 (2010).
113. prostaglandin E2 in podosome dissolution and induction of high-speed migration during dendritic cell maturation. J. Immunol. 177(3), 1567-1574 (2006).
114. Yen JH, Khayrullina T, Ganea D: PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 111(1), 260-270 (2008).
115. Wang H, Hao Q, Li QR et al.: Omega-3 polyunsaturated fatty acids affect lipopolysaccharide-induced maturation of dendritic cells through mitogen-activated protein kinases p38. Nutrition 23(6), 474-482 (2007). (Pubitemid 46891768)
116. Zeyda M, Saemann MD, Stuhlmeier KM et al.: Polyunsaturated fatty acids block dendritic cell activation and function independently of NF-kB activation. J. Biol. Chem. 280(14), 14293-14301 (2005). (Pubitemid 40517332)
117. Attakpa E, Hichami A, Simonin AM, Sanson EG, Dramane KL, Khan NA: Docosahexaenoic acid modulates the expression of T-bet and GATA-3 transcription factors, independently of PPARa, through suppression of MAP kinase activation. Biochimie 91(11-12), 1359-1365 (2009).
118. Ariel A, Li PL, Wang W et al.: The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 280(52), 43079-43086 (2005). (Pubitemid 43049274)